HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Brenner, Bluma Ga; Oliveira, Maureena; Doualla-Bell, Florencea,b; Moisi, Daniela Da; Ntemgwa, Michela; Frankel, Fernandoa; Essex, Maxb; Wainberg, Mark Aa
From the aMcGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
bBotswana-Harvard Laboratory, Gaborone, Botswana.
Received 31 January, 2006
Revised 9 March, 2006
Accepted 13 March, 2006
Correspondence to Mark A. Wainberg, McGill AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2. Tel: +1 514 340 8260; fax: +1 514 340 7537; e-mail: email@example.com
Background: Genotypic diversity among HIV-1 subtypes and circulating recombinant forms (CRF) may lead to distinct pathways to drug resistance. This study evaluated subtype-related differences in the development of resistance in culture to tenofovir.
Methods: Genotyping determined nucleotide diversity among subtypes. Representative subtype B, C, CRF1_AE, CRF2_AG, G, and HIV-2 isolates were selected for resistance to tenofovir, lamivudine and didanosine in cell culture. Phenotypic assays determined the effects of the K65R substitution in reverse transcriptase (RT) on drug susceptibility.
Results: Subtype C isolates show unique polymorphisms in RT codons 64 (AAG→AAA), 65 (AAA→AAG), and 66 (AAA→AAG), absent in other subtypes. The K65R mutation (AAG→AGG) arose with tenofovir by week 12 in four subtype C selections. In contrast, no tenofovir resistance arose in four subtype B (> 34–74 weeks), one each of CRF2_AG and G (> 30–33 weeks), and three HIV-2 (> 27–28 weeks) selections. K65R appeared after 55 and 73 weeks in two CRF1_AE selections with tenofovir. In contrast, times to the appearance of M184V with lamivudine pressure (weeks 8–14) did not vary among subtypes. Selective didanosine pressure resulted in the appearance of M184V and L74V after 38 weeks in two of four subtype C selections. The K65R transitions in subtype C and other subtypes (AGG and AGA) conferred similar 6.5–10-fold resistance to tenofovir and five to 25-fold crossresistance to each of abacavir, lamivudine, and didanosine, while not affecting zidovudine susceptibility.
Conclusion: Tenofovir -based regimens will need to be carefully monitored in subtype C infections for the possible selection of K65R.
The emerging epidemics in Africa and Asia show increasing genetic diversification, with a shift towards non-B subtypes and circulating recombinant forms (CRF) [1–3]. Effective strategies must be developed to handle this growing wave of non-B infections with particular emphasis on subtypes C and A (including CRF1_AE and CRF2_AG), which presently account for over 50 and 30% of new infections worldwide, respectively [3,4].
Natural polymorphisms in non-B subtypes may influence drug susceptibility, therapy response and emerging pathways to drug resistance [5–10]. HIV-1 subtypes can vary by 10–15% in nucleotides and 5–10% in amino acids in the pol gene encoding reverse transcriptase (RT) and protease . Our laboratory has described a subtype C signature mutation in which a valine polymorphism (GTG) codon at 106 facilitates a V106M transition (GTG→ATG) that confers resistance to non-nucleoside RT inhibitors .
Resistance to tenofovir is extremely difficult to select in culture , although the K65R mutation in RT is associated with such resistance in the clinic. In this study, we describe signature nucleotide polymorphisms in subtype C viruses at RT codons 64, 65, and 66, which may be implicated in emergent resistance to tenofovir. We evaluated the differential times to the development of resistance to tenofovir in cell culture comparing subtype C to other HIV subtypes.
Materials and methods
Viral isolates and selection of drug resistance
Subtype C viral isolates used in this study included BG-05 (AF492600), BG-15 (AF492601), and Mole 18 (AF492607) from Botswana and 4742 (AF492595) from Ethiopia [13,14]. Blood samples harbouring subtype A (n = 1), CRF1_AE (n = 2), CRF2_AG (n = 1), B (n = 4), G (n = 1) viruses were also obtained from treatment-naive patients in Montreal with ethics approval. Viruses were isolated by co-culture of peripheral blood mononuclear cells with cord blood mononuclear cells (CBMC) as previously described [14,15]. The GenBank accession numbers for the Quebec non-B isolates are as follows: 6050 (subtype A-DQ380550), 6343 (CRF1_AE-DQ380549), 6240 (CRF1_AE-DQ385889), 6383 (CRF2_AG-DQ380551), and 5880 (G-DQ380550).
The selection of drug-resistant subtype variants was performed by repeated serial passage of viruses in CBMC in the presence of increasing concentrations of drugs for up to 73 weeks for tenofovir, 30 weeks for lamivudine, and 40 weeks for didanosine. RT assays were performed weekly to assess viral replication . Drug concentrations were escalated over time to maintain effective antiviral pressure, i.e. RT activities (> 10% and < 50%) compared with control cultures grown in the absence of drug. Genotyping was performed at select passages to evaluate time to the development of drug resistance.
Genotypic and phenotypic resistance testing
The sequencing of extracted RNA or complementary DNA was performed by Bayer TruGene or by ABI technology to determine genotypic changes associated with drug resistance . Drug susceptibility was measured in cell culture-based phenotypic assays, determining the extent to which antiretroviral drugs inhibit in-vitro HIV replication. Briefly, CBMC were infected with different subtype viral isolates and the 50% drug inhibitory concentrations (IC50) were ascertained for tenofovir and nucleoside analogues, including zidovudine, lamivudine, abacavir, and didanosine, both pre and post-selection with tenofovir [14,15].
Nucleotide polymorphisms surrounding reverse transcriptase codon 65 in different subtypes
We examined non-B subtype sequences from the Quebec provincial genotyping program to identify natural nucleotide polymorphisms in the HIV-1 RT region that might be implicated in emergent drug resistance. Of note was the fact that subtype C viruses (n = 91/95) show a signature pattern of nucleotide polymorphisms compared with subtype B at RT codons 64 (AAG→AAA), 65 (AAA→AAG), and 66 (AAA→AAG), i.e. a KKK motif. This pattern is specific for subtype C. The codon 64 and codon 65 transitions are absent in subtype B (n = 0/49), A/CRF1_AE (0/35), and CRF2_AG (n = 1/35) infections. The codon 66 polymorphism was, however, observed in 22.4, 37 and 23% of subtype B, A/CRF1_AE and CRF2_AG isolates, respectively. The KKK amino acid motif was common at RT positions 64, 65 and 66 in all subtypes before selection for resistance.
Time to selection of tenofovir resistance in cell culture in different subtypes
To ascertain whether the nucleotide polymorphisms surrounding codon 65 may be implicated in resistance to tenofovir, four representative subtype B and C isolates were passaged in increasing dosages of tenofovir. As shown in Fig. 1, concentrations of tenofovir could be escalated more rapidly in subtype C selections. All four subtype C isolates developed K65R (AAG→AGG) within 12 weeks of serial passage in tenofovir, as rapidly as M184V was selected with lamivudine (Table 1). In contrast, none of the subtype B variants developed K65R in the last time of serial passage, i.e. weeks 34–74 (Table 1). Similarly, none of the subtype A, CRF1_AE, CRF2_AG or G isolates developed K65R at weeks 30–33 of serial passage in tenofovir, although the two CRF1_AE isolates were observed to develop K65R at weeks 55 and 73 (Table 1).
Facilitated development of tenofovir resistance in subtype C viruses
To ascertain whether the rapid development of K65R in subtype C viruses may be caused by virulence or replicative fitness, viral isolates were also selected for resistance to lamivudine and didanosine in parallel to tenofovir. No significant differences in times to the development of resistance to lamivudine were observed for all isolates tested, and M184I/V emerged by weeks 8–14 (Table 1). Of note is the fact that resistance to didanosine developed with two subtype C selections with the first emergence of M184V and L74V between weeks 22 and 25 (Table 1). No resistance-conferring mutations were detected by weeks 37–40 in the presence of didanosine with the remaining subtype B and C isolates (Table 1).
The levels of RT activity in amplified K65R viral stocks grown in the absence of drug were compared with matched wild-type controls. The replicative capacities (mean ± SEM) of the four K65R-containing subtype C isolates and the two K65R-containing subtype CRF1_AE isolates, compared with matched wild-type controls, were 62 ± 7 and 51 ± 3%, respectively, compared with 46 ± 5% for the K65R-containing recombinant B clone compared with wild type.
Drug susceptibility of K65R
Phenotypic drug susceptibility testing was performed to ascertain the drug sensitivity and resistance profiles of different viral subtypes. The baseline IC50 values for tenofovir sensitivity of the four subtype C isolates was 0.48 ± 0.18 μmol, within a similar range, 0.25 ± 0.15 μmol was observed for subtype B infections. Subtype C and CRF1_AE viruses harbouring K65R were assayed for their relative susceptibility to tenofovir and nucleoside analogues. As shown in Fig. 2, all variants harbouring K65R showed similar 6.5 to 10-fold resistance to tenofovir. These viruses also showed 8–22 ×, 10–23 ×, and 3–16 × levels of resistance to abacavir, lamivudine and didanosine, respectively. These viruses all remained susceptible to zidovudine.
Tenofovir has been proposed as a drug of choice in antiviral drug strategies directed against the global pandemic , as a result of its favourable resistance profile, long intracellular half-life, and marginal adverse effects [17–20]. Current guidelines recommend tenofovir/emtricitavudine (Truvada) or zidovudine/lamivudine (Combivir) with efavirenz as two first-line treatments of choice for antiretroviral-naive patients . Clinical trials to evaluate the efficiency of tenofovir in pre-exposure prophylaxis have been initiated in Africa, Asia, and the United States . Among the reasons for choosing tenofovir over such drugs as lamivudine has been the reduced risk of developing resistance to tenofovir via the K65R mutation.
We have now demonstrated that tenofovir can rapidly select K65R in subtype C viruses in cell culture. The appearance of K65R with tenofovir is as rapid as that of M184V with lamivudine. These findings indicate that tenofovir-based regimens in subtype C infections will need to be carefully monitored. A recent report suggested that K65R is less prevalent in patients harbouring subtype A than in subtype B and C infections . On the basis of our findings, the reduced prevalence of K65R in subtype A may partly be explained by a higher rate of selection in subtype C infections.
The mechanisms involved in the more rapid selection of K65R among subtype C viruses may relate to the sequences that naturally encode a wild-type KKK motif at codons 64, 65 and 66. Only a single point mutation is required for the emergence of K65R in each of the viral subtypes evaluated. Conceivably, the nucleotide environment of the position 65 codon plays a role in governing the frequency of K65R substitutions, allowing for the more rapid amplification of K65R viruses under conditions of drug pressure. It does not appear that K65R subtype C variants are less impacted in terms of replication capacity, compared with wild-type, than subtype B viruses containing this same substitution .
There are potential limitations in extrapolating in-vitro selection data to the in-vivo situation. Site-directed mutagenesis studies in which the AAA codon 65 of a subtype B clone is replaced by AAG and in which the AAG at codon 65 in subtype C viruses is replaced by AAA are ongoing. Previous work showing that a V106M substitution in subtype C viruses is selected by efavirenz provides proof of concept that in-vitro findings may be reflected in the clinical setting . Several recent studies have shown non-responsiveness to tenofovir/lamivudine/abacavir regimens, leading to the rapid appearance of K65R in 48–68% of patients [24,25]. In contrast, the 934 study showed clinical benefit of a tenofovir/emtricitabine/efavirenz regimen with no appearance of K65R . Such studies demonstrated that drug potency, low genetic barrier to tenofovir resistance, and physiological factors may all contribute to differential responsiveness to tenofovir . Our study highlights the need for careful evaluation of tenofovir-based regimens in subtype C infections.
Although the K65R mutation remains relatively uncommon, an increase in its prevalence in western countries has been observed over the past 4 years, as a result of the increased clinical use of tenofovir [26,28–30]. The K65R mutation may also be associated with the Q151M resistance pathway . Our group has shown with others that three out of eight treated patients in Botswana developed K65R with didanosine-containing regimens . Of note is the fact that the the four subtype C isolates selected with didanosine in this study did not develop K65R, although M184V and L74V were observed in two selections.
It is still unknown whether K65R will become increasingly prevalent in subtype C infections after the usage of tenofovir. Our findings indicate the need for vigilance in adapting antiretroviral regimens and prophylactic schedules for use in developing countries, and that subtype differences in regard to the development of drug resistance need to be carefully monitored whenever antiretroviral drugs are introduced.
Sponsorship: This work was sponsored by the Canadian Institutes for Health Research (CIHR), the Canadian Foundation for AIDS research (CANFAR), and Fonds de la Recherche en Santé du Québec-SIDA (FRSQ-SIDA).
1. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. The impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51:229–240.
2. Essex M, Mboup S. Regional variations in the African epidemics. In: Essex M, Mboup S, Kanki PJ, Marlink RG, Tlou SD, editors. AIDS in Africa. New York: Kluwer/Plenum Publishers; 2002.
3. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al
. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLOS Med 2005; 2:325–337.
4. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. WHO–UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29:184–190.
5. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al
. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1–F5.
6. Abecasis AB, Deforche K, Snoeck J, Bacheler L, McKenna P, Carvalho AP, et al
. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C. F or G AIDS 2005; 19:1799–1806.
7. Eshleman S, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, et al
. Distinct Patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005; 40:24–29.
8. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, Tong CYW. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005; 19:1916–1919.
9. Grossman Z, Istomin V, Averbach D, Lorber M, Risenberg K, Levi I, et al
. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18:909–915.
10. Grossman Z, Paxinos EE, Averback D, Maayan S, Parkin NT, Engelhard D, et al
. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159–2165.
11. Turner D, Brenner B, Moisi D, Detorio M, Cesaire R, Kurimuri T, et al
. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B subtype HIV-1 variants. Antimicrob Agents Chemother 2004; 48:2993–2998.
12. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al
. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther 1999; 4:87–94.
13. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al
. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002; 56:129–142.
14. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al
. Genetic divergence of HIV-1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46:2087–2094.
15. Salomon H, Belmonte A, Nguyen K, Gu Z, Gelfand M, Wainberg MA. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol 1994; 32:2000–2002.
16. Wainberg MA. Generic HIV drugs-enlightened policy for global health. N Engl J Med 2005; 352:747–750.
17. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev 2005; 4:928–940.
18. Gallant JE, Deresinski S. Tenofovir disproxyl fumarate. Clin Infect Dis 2003; 37:849–859.
19. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Sulieman JM, Miller MD, et al
. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. JAMA 2004; 292:191–201.
20. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al
. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733–2739.
21. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Available at: http://AIDSinfo.nih.gov
. Accessed: 6 October 2005.
22. Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, Cohen MS, et al
. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005; 309:2170–2171.
23. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437–3446.
24. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al
. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921–1930.
25. Delauney C, Brun-Vezinet F, Landman R, Collin G, Peytavin G, Trylesinski A, et al
. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005; 79:9572–9578.
26. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al
. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251–260.
27. Kuritkes DR. Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J Infect Dis 2005; 192:1867–1868.
28. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949–951.
29. Valer L, Martin-Carbonero L, de Mendoza C, Corral A, Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004; 18:2094–2096.
30. Gianotti N, Seminari E, Fusetti G, Salpietro S, Boeri E, Galli A, et al
. Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. AIDS 2004; 18:2205–2208.
31. Doualla-Bell F, Gaseitsiwe S, Ndung'u T, Modukanele M, Peter T, Novitsky V, et al
. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 2004; 15:189–200.
This article has been cited 64 time(s).
AIDS Research and Human RetrovirusesHIV-1 Subtype Distribution Trends and Evidence of Transmission Clusters Among Incident Cases in a Rural Clinical Cohort in Southwest Uganda, 2004-2010AIDS Research and Human Retroviruses
Cold Spring Harbor Perspectives in MedicineThe HIV-1 Epidemic: Low- to Middle-Income CountriesCold Spring Harbor Perspectives in Medicine
VirologyConnection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceVirology
Plos OneMonitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate?Plos One
Journal of the International AIDS SocietyVirological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in CameroonJournal of the International AIDS Society
Plos OnePotential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited SettingsPlos One
Journal of Antimicrobial ChemotherapyOnce-daily dosing of nevirapine in HAARTJournal of Antimicrobial Chemotherapy
Characterization and Structural Analysis of HIV-1 Integrase Conservation
AIDS Reviews, 11(1):
RetrovirologyComparative biochemical analysis of HIV-1 subtype B and C integrase enzymesRetrovirology
Plos MedicineCriteria for drugs used in pre-exposure prophylaxis trials against HIV infectionPlos Medicine
Antiviral TherapyEffects of HIV type-1 immune selection on susceptability to integrase inhibitor resistanceAntiviral Therapy
Journal of Infectious DiseasesSlow Accumulation of HIV Resistance Mutations: Implications for Resource-Limited Settings?Journal of Infectious Diseases
RetrovirologyNew pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and fluRetrovirology
AIDS Research and Human RetrovirusesDrug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: Population and clonal sequence analysisAIDS Research and Human Retroviruses
New England Journal of Medicine
Medical progress: The challenge of HIV-1 subtype diversity
New England Journal of Medicine, 358():
Journal of Antimicrobial ChemotherapyHigh rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsJournal of Antimicrobial Chemotherapy
Antimicrobial Agents and ChemotherapyHigh prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimensAntimicrobial Agents and Chemotherapy
Journal of VirologyCandidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine modelJournal of Virology
The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa
Antiviral Therapy, 13(5):
AIDS Research and Human RetrovirusesHIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, BrazilAIDS Research and Human Retroviruses
RetrovirologyEffects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistanceRetrovirology
Antimicrobial Agents and ChemotherapyReverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesAntimicrobial Agents and Chemotherapy
Journal of VirologyTemplate Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1Journal of Virology
Antiviral ResearchGenotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naive and treated subjectsAntiviral Research
Journal of Medical VirologyPrevalence of the K65R Resistance Reverse Transcriptase Mutation in Different HIV-1 Subtypes in IsraelJournal of Medical Virology
Plos MedicineAntiretroviral therapy for prevention of HIV infection: New clues from an animal modelPlos Medicine
Lancet Infectious Diseases
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review
Lancet Infectious Diseases, 10(3):
AIDS Research and Human RetrovirusesHIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral TherapyAIDS Research and Human Retroviruses
Journal of VirologyReplicative Capacity Differences of Thymidine Analog Resistance Mutations in Subtype B and C Human Immunodeficiency Virus Type 1Journal of Virology
AIDS Research and Human RetrovirusesSingle-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTsAIDS Research and Human Retroviruses
Plos PathogensTheme and variations in the evolutionary pathways to virulence of an RNA plant virus speciesPlos Pathogens
Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations
Antiviral Therapy, 13(2):
American Journal of Reproductive ImmunologyImpact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tractAmerican Journal of Reproductive Immunology
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
AIDS Reviews, 10(2):
Antiviral ResearchPerspectives on antiviral drug developmentAntiviral Research
Journal of Infectious Diseases
Chemoprophylaxis of HIV infection: Moving forward with caution
Journal of Infectious Diseases, 194(7):
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
Antiviral Therapy, 12(8):
Proceedings of the National Academy of Sciences of the United States of AmericaThe paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsProceedings of the National Academy of Sciences of the United States of America
Journal of Clinical VirologyEvolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypesJournal of Clinical Virology
Plos OneThe HIV-1 Subtype C Epidemic in South America Is Linked to the United KingdomPlos One
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme
Antiviral Therapy, 14(4):
AIDS Research and Human RetrovirusesChanges in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in SpainAIDS Research and Human Retroviruses
Antiviral TherapyProgress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance WorkshopAntiviral Therapy
Plos OneNucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance MutationPlos One
Clinical Infectious DiseasesAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelClinical Infectious Diseases
Future VirologyAntiviral drug development: progress and pitfallsFuture Virology
Role of Genetic Diversity amongst HIV-1 Non-B Subtypes in Drug Resistance: A Systematic Review of Virologic and Biochemical Evidence
AIDS Reviews, 10(4):
Antimicrobial Agents and ChemotherapyNucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2Antimicrobial Agents and Chemotherapy
Journal of Infectious DiseasesSignature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV-1 Subtype CJournal of Infectious Diseases
AIDS Research and Human RetrovirusesDiscrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfectionAIDS Research and Human Retroviruses
VirologyThe increasing prevalence of HIV-1 subtype C in Southern Brazil and its dispersion through the continentVirology
Journal of Infectious DiseasesNucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out StavudineJournal of Infectious Diseases
Current Opinion in Infectious DiseasesImpact of HIV-1 pol diversity on drug resistance and its clinical implicationsCurrent Opinion in Infectious Diseases
JAIDS Journal of Acquired Immune Deficiency SyndromesVaried Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes
JAIDS Journal of Acquired Immune Deficiency SyndromesClinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in NigeriaJAIDS Journal of Acquired Immune Deficiency Syndromes
HIV-1 subtype diversity; K65R; subtype C; tenofovir
© 2006 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.